Intrinsiqq
Kalaris Therapeutics, Inc. logo

Kalaris Therapeutics, Inc.

KLRS

Compare

Valuation & Multiples

Based on TTM earnings · Diluted shares

Market Cap$30M
EPS-$0.48
P/E-2.67
P/FCF-0.76
EV/EBITDA1.09
FCF Yield–
Div. Yield–
Net Debt/FCF2.0x
Kalaris Therapeutics, Inc. intrinsic value
52-Week Range
$1.28$3.63

Profitability & Returns

Revenue

N/A

Net Income (TTM)

-$43M

▲ +37.2% YoY

Op. Margin

–

ROIC

-57.35%

▼ -9.1pp YoY

Cash Flow & Balance Sheet

FCF (TTM)

-$40M

▼ -86.6% YoY

Op. Cash Flow (TTM)

-$40M

▼ -85.6% YoY

Net Debt

-$82M

Net Cash Position

Cash & Equiv.

$83M

Continue Research

Peers

Biological Products, (No Diagnostic Substances) · Pick stocks to compare with KLRS

CompareIntrinsic value
ATYRAtyr Pharma Inc.
$3.82+3.52%10
WINTWindtree Therapeutics Inc.
$0.00-33.33%10
ZIVOZivo Bioscience Inc.
$5.50+0.00%0
VIVSVivoSim Labs, Inc.
$0.26-10.34%10
AIMAIM ImmunoTech Inc.
$0.11-4.50%25
ARTVArtiva Biotherapeutics Inc.
$3.78-1.31%10
IKTInhibikase Therapeutics Inc.
$1.31+0.38%10
CVMCel-Sci Corporation
$1.21-17.69%0

Kalaris Therapeutics (KLRS) in three numbers

Quality score
10/100
Best check: net debt, -$82M. Weakest: return on capital, -57.4%.
Quality
Dividend
None
No dividend in the SEC filings we hold.
Dividends
P/E
-2.67
Negative: a loss over the last twelve months. Price to free cash flow -0.76.
Financials

Questions about Kalaris Therapeutics

Is Kalaris Therapeutics a high-quality business?

Kalaris Therapeutics scores 10 out of 100 on Intrinsiqq's quality score, which makes it a lower-quality business on these measures. The score blends 3 checks computed from SEC filings. Its best check is net debt at -$82M, and its weakest is return on capital at -57.4%. The Quality tab shows every check against its target.

Does Kalaris Therapeutics (KLRS) pay a dividend?

No. Kalaris Therapeutics (KLRS) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Nor has its share count fallen meaningfully over the last twelve months, so cash is kept in the business. The Dividends tab shows its cash returns.

Source: 10-Q filed 3 Nov 2026 (period ending 30 Sept 2026), SEC. Price: last close 20 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.

Spot a number that looks wrong? Check it in KLRS's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

5 of 5 free stocks used today

Keep analysing KLRS

A free account gives you 10 stocks a day, a watchlist and price alerts.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.

MarketsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.